AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 156 filers reported holding AGIOS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 1.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $17,403,000 | -71.4% | 785,000 | -62.4% | 1.47% | -46.1% |
Q1 2022 | $60,840,000 | -11.4% | 2,090,000 | 0.0% | 2.73% | +40.9% |
Q4 2021 | $68,698,000 | -31.2% | 2,090,000 | -3.5% | 1.94% | -22.2% |
Q3 2021 | $99,915,000 | -16.3% | 2,165,000 | 0.0% | 2.49% | -17.9% |
Q2 2021 | $119,313,000 | +6.7% | 2,165,000 | 0.0% | 3.03% | -9.0% |
Q1 2021 | $111,801,000 | +8.6% | 2,165,000 | -8.8% | 3.33% | +9.2% |
Q4 2020 | $102,909,000 | +68.0% | 2,375,000 | +35.7% | 3.05% | +11.2% |
Q3 2020 | $61,250,000 | +7.0% | 1,750,000 | +63.6% | 2.74% | -19.0% |
Q2 2020 | $57,224,000 | +50.7% | 1,070,000 | 0.0% | 3.39% | -16.0% |
Q1 2020 | $37,964,000 | -3.6% | 1,070,000 | +29.7% | 4.03% | +11.2% |
Q4 2019 | $39,394,000 | -99.9% | 825,000 | -11.8% | 3.62% | +15.6% |
Q3 2019 | $30,294,000,000 | +22.7% | 935,000 | +88.9% | 3.14% | +35.7% |
Q2 2019 | $24,690,600,000 | +109189.1% | 495,000 | +47.8% | 2.31% | -6.9% |
Q1 2019 | $22,592,000 | +10.1% | 335,000 | -24.7% | 2.48% | -29.3% |
Q4 2018 | $20,519,000 | -54.1% | 445,000 | -23.2% | 3.51% | -35.4% |
Q3 2018 | $44,712,000 | +45.5% | 579,776 | +58.9% | 5.43% | +26.5% |
Q2 2018 | $30,725,000 | +3.0% | 364,776 | 0.0% | 4.30% | -18.1% |
Q1 2018 | $29,831,000 | +63.1% | 364,776 | +14.0% | 5.25% | +17.8% |
Q4 2017 | $18,294,000 | +7.5% | 320,000 | +25.5% | 4.46% | -7.3% |
Q3 2017 | $17,021,000 | +29.7% | 255,000 | 0.0% | 4.81% | -1.0% |
Q2 2017 | $13,120,000 | -5.4% | 255,000 | +7.4% | 4.85% | -40.7% |
Q1 2017 | $13,870,000 | +38.2% | 237,500 | -1.2% | 8.18% | -1.3% |
Q4 2016 | $10,036,000 | -32.7% | 240,500 | -14.9% | 8.29% | -31.4% |
Q3 2016 | $14,919,000 | +89.9% | 282,443 | +50.6% | 12.08% | +54.5% |
Q2 2016 | $7,855,000 | +30.7% | 187,500 | +26.7% | 7.82% | +13.4% |
Q1 2016 | $6,009,000 | -8.8% | 148,000 | +45.8% | 6.90% | +18.5% |
Q4 2015 | $6,590,000 | – | 101,500 | – | 5.82% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Flagship Ventures 2007 General Partner LLC | 1,930,369 | $118,428,000 | 83.56% |
Third Rock Ventures, LLC | 3,070,090 | $188,350,000 | 21.97% |
Opaleye Management Inc. | 113,500 | $6,963,225,000 | 5.43% |
BB BIOTECH AG | 1,890,521 | $115,983,000 | 4.72% |
Eventide Asset Management | 431,600 | $26,479,000 | 3.70% |
Atika Capital Management LLC | 54,000 | $3,313,000 | 2.55% |
Cormorant Asset Management, LP | 100,000 | $6,135,000 | 1.26% |
BRIDGER MANAGEMENT, LLC | 220,099 | $13,503,000 | 0.92% |
Ghost Tree Capital, LLC | 20,000 | $1,227,000 | 0.67% |
HAMILTON LANE ADVISORS LLC | 27,544 | $1,690,000 | 0.55% |